Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate)

Summary

This study is a multi-center, randomized, placebo-controlled study to evaluate the long-term safety of Perforomist® inhalation therapy in subjects with Chronic Obstructive Pulmonary Disease (COPD). Individual participation is approximately 54 weeks, including 52 weeks of double-blind treatment.

Timeline

Start

2012-03

Primary completion

2016-01

Completion

2016-01

Drugs

Indications